Epithalon activates telomerase, modulates melatonin synthesis, and has shown lifespan extension in multiple rodent models. The human evidence comes almost entirely from Soviet-era observational studies — here's how to read it correctly. Historical articles may no longer reflect current regulatory status. Check the cited primary source.
Epithalon (AEDG tetrapeptide; Ala-Glu-Asp-Gly) is a synthetic version of a pineal gland extract called epithalamin, studied extensively in the Soviet Union from the 1970s onward by the St. Petersburg Institute of Bioregulation and Gerontology. The research body is substantial by peptide standards: 155 indexed PubMed citations, human observational data, and documented lifespan extension in rodent models.
It is also almost entirely the product of a single research group, has no Western RCTs, and has a withdrawn FDA nomination with continuing safety concerns.
Epithalon has been documented to activate telomerase (hTERT) in human fibroblast cultures — meaning it enables cells to maintain or extend their telomeres during replication. This is the primary mechanism cited in longevity contexts. The downstream claim is that extended telomeres correlate with cellular longevity and reduced senescence.
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy
The evidence for this mechanism is from cell culture and animal models. The translation to meaningful human telomere biology effects from exogenous administration remains unestablished.
Beyond telomerase activation, the 2025 International Journal of Molecular Sciences review documents: melatonin synthesis modulation via AANAT/pCREB pathways, epigenetic regulation through histone H1 binding, IL-2 mRNA modulation, and reduction of reactive oxygen species. Epithalon also shows geroprotective activity in rodent models — extended maximum lifespan in CBA mice by 11.9%, reduced tumor incidence.
The human data for Epithalon consists primarily of small observational studies from a single Russian research group, published largely in Russian-language journals. Western peer-review replication is minimal. This is not evidence that the compound doesn't work — it is a significant limitation on the strength of any claim about it.
PeptideX assigns Epithalon a confidence score of 3/5: Human Observational evidence tier, recognizing the human data while flagging its significant limitations. A score of 4 would require an independent human RCT. A score of 5 would require multiple.
HHS proposed 503A enforcement discretion (not final). FDA substance context: Epitalon (Epithalon). Named in the proposed HHS 503A enforcement-discretion notice (Federal Register 2026-22192, October 2026). The policy is proposed, not final, and is not FDA approval. FDA's earlier record lists the nomination as withdrawn from Category 2 with potential significant safety risks. Regulatory source checked October 29, 2026. Sources: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Full compound profile: peptidex.ai/compounds/epithalon
*This content is for educational and informational purposes only. Not medical advice. See full Research Disclaimer.*
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy